

# TABLE OF CONTENTS

June 15, 2009

No. 2143

## BUSINESS

- 1 Asahi Kasei to Enhance Focus on Pharma Business
- 2 Meiji Aims at Pharma Sales of ¥145.0 Bil. in FY2011
- 2 Meiji Licenses out ME3301 to Amalyte
- 3 JCR Pharmaceuticals Expects Launching of EPO Biosimilar in April 2010
- 3 GSK, Pola to Copromote GSK's 4 Topical Agents
- 4 Combined Operating Profits of 21 JPMA Members Plummet 13.7%
- 6 **BUSINESS NEWS IN BRIEF**
  - Seikagaku Allies with Zimmer for Marketing Gel-200 in the US
  - GSK to Copromote Botox with Wakamoto in Ophthalmology
  - Bayer HealthCare, Genzyme Finalize Strategic Alliance Agreement
  - Quintiles to Soon Begin Organizational Diagnosis Service Q-DOC

## SELF-MEDICATION

- 7 Tsumura: Record-High Profits Focusing on *Kampo* Medicines
  - New Mid-Term Plan Calls For Sales of ¥104.3 Bil. in FY2011
  - Establishing *Kampo* Medicine as Science
  - Reasons for Withdrawal from JPMA
- 7 **SELF-MEDICATION NEWS IN BRIEF**
  - Takeda to Launch New Series of OTC Drugs for GI Disorders

## REGULATORY

- 8 Industry Leaders Advocate Price Cut Exemption for Innovative Drugs at *Chuikyo*
  - ARBs, Statins Will Not Be Eligible for Exemption
  - Development of Unapproved Drugs to Be Supported by JPMA
  - Original Makers Should Not Interfere with Use of Generics: Mr Yamamoto
  - Price Cut Exemption System to Increase Priority of Investment in Japan: Mr Dunoyer
  - FJPWA to Cooperate to Increase Use of Generics: Mr Bessho
  - Conclusion Must Be Drawn by Year-End: Mr Isobe
  - JMA Doesn't Accept Industry's Proposal as Is
- 11 FPMAJ Proposes Replacement of Cost Calculation Method with a New One
  - New Pricing Rule for Biosimilars
- 14 More Drugs Granted Premiums: Mr Nakagaki
- 14 Sandoz's Somatropin to Be Approved as 1st Biosimilar Based on New Guidance
  - Caduet to Be Approved as 1st Combination of Ca Blocker and Statin

- Aliskiren, Mirtazapine, Bimatoprost Recommended for Approval
- 16 Proposed Q&A for Guidance on Biosimilars Released

## R&D

- 17 MAA for Alogliptin in the EU to Be Delayed Until 2012: Takeda
- 17 NAD for Au AA21004 Also Be Delayed: Takeda
- 18 **R&D NEWS IN BRIEF**
  - AstraZeneca, Merck Tie Up for New Combination Anticancer Drug
  - Merck Serono Begins PIII Trial of Erbitux for Gastric Cancer in Japan
  - Solasia Submits CTA for SP-01 in China
  - Good PII Results with Lurasidone Published: DSP
  - Bayer Schering Presents PII Study Results of Riociguat for PAH
  - QAB149 Improves Lung Function in COPD: Novartis
  - Hokunalin Tape Improves QOL of COPD Patients: Abbott Japan, Maruho
  - Kaletra + Raltegravir Combination Rapidly Decreases Viral Load
  - Actemra Inhibits Joint Structural Damage in RA: Chugai
  - Unapproved Drugs Development Support Center Created by JPMA

## NEW PRODUCTS

- 20 **NEW PRODUCTS**
  - Vero Cell-derived Japanese Encephalitis Vaccine Released

## OPINION

- 21 **OPINION**
  - Why Empathy Is Key in Closing: Philip Carrigan

## MEDICAL FACILITIES & NURSING CARE

- 22 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
  - Main Driver of Med Expenses Is Dispensing Services, Not Drugs: JMA Revises Earlier Statement
  - Causal Relationship between Tamiflu and Abnormal Behavior Not Confirmed: Working Group
  - Relenza's Validity Extended to 7 Years

## TOPICS

- 22 **TOPICS**
  - *Kyokaikenpo* to Distribute Generics Request Card to Help Patients Request Generics

## MEDICAL DEVICES

- 23 **MEDICAL DEVICE NEWS IN BRIEF**
  - Sanko Junyaku to Launch NANOPIA KL-6 Eisai
  - Wako Pure Chemical:  $\mu$ TASWako i30 to Determine Markers for Hepatocellular Carcinoma
  - Yamasa to Market Dako's Flow Cytometry Antibodies